Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,012.82
-1.77 (-0.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
34
35
Next >
Should You Buy the Dip on This Top Growth Stock?
Today 6:30 EDT
The biotech needs to overcome an issue most drugmakers face at some point.
Via
The Motley Fool
A Closer Look at 24 Analyst Recommendations For Regeneron Pharmaceuticals
October 04, 2024
Via
Benzinga
Market Whales and Their Recent Bets on REGN Options
October 03, 2024
Via
Benzinga
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
October 03, 2024
Via
Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today
September 30, 2024
Via
Benzinga
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
September 29, 2024
10 worst performing large-cap stocks last week: SMMT, MMYT, MEDP, REGN, GPN, AFRM, SMCI, FTI, FCNCA, NOW. Are they in your portfolio?
Via
Benzinga
A Closer Look at Regeneron Pharmaceuticals's Options Market Dynamics
September 25, 2024
Via
Benzinga
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
September 25, 2024
Via
Benzinga
Smart Money Is Betting Big In REGN Options
September 23, 2024
Via
Benzinga
Stock Market Rally Hits Fresh Highs, Fueled By Micron Earnings, China Stimulus: Weekly Review
September 27, 2024
The S&P 500 hit record highs, fueled by Micron and Chinese stimulus.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
September 27, 2024
The FDA approved Regeneron and Sanofi's Dupixent as an add-on treatment for inadequately controlled COPD, demonstrating significant reductions in exacerbations and improved lung function in Phase 3...
Via
Benzinga
Exposures
Product Safety
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
September 27, 2024
The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD.
Via
Investor's Business Daily
Exposures
Product Safety
Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'
September 26, 2024
Analyst Stephen Weiss of Short Hills Capital Partners said he still finds Taiwan Semiconductor Manufacturing Company cheap.
Via
Benzinga
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
September 11, 2024
Via
Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,000 Today
September 10, 2024
Via
Benzinga
Beyond The Numbers: 20 Analysts Discuss Regeneron Pharmaceuticals Stock
September 09, 2024
Via
Benzinga
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
September 25, 2024
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent...
Via
Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
September 24, 2024
Regeneron filed an appeal after a court's decision, which was issued under seal.
Via
Benzinga
This BP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
September 24, 2024
Via
Benzinga
Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling
September 23, 2024
The EV giant, once a big S&P 500 laggard in 2024, is now up for the year.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
September 23, 2024
Eylea is one of Regeneron's biggest moneymakers, and Amgen is looking to knock it off.
Via
Investor's Business Daily
Evaluating Regeneron Pharmaceuticals Against Peers In Biotechnology Industry
August 27, 2024
Via
Benzinga
What Analysts Are Saying About Regeneron Pharmaceuticals Stock
August 23, 2024
Via
Benzinga
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...
Via
Talk Markets
Topics
ETFs
Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease
September 11, 2024
Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints.
Via
Benzinga
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits
September 11, 2024
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits
Via
News Direct
Prediction: These 2 Companies Will Split Their Stocks by 2027
September 11, 2024
Eli Lilly and Regeneron Pharmaceuticals are good stock-split candidates thanks to years of successes.
Via
The Motley Fool
Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030
September 05, 2024
These stocks have generally delivered competitive returns.
Via
The Motley Fool
Biotech And Life Science Sector Update Summer Of 2024
August 29, 2024
It’s the slowest week of the year, we are at the market top and most earnings reports are good.
Via
Talk Markets
10 Bagger Stocks: Can You Find One?
August 23, 2024
Finding 10 baggers is not easy, but it’s a worthwhile pursuit for long-term investors.
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
...
34
35
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.